Revolution Medicines, Inc. (FRA:42Z)

Germany flag Germany · Delayed Price · Currency is EUR
67.00
+1.00 (1.52%)
Last updated: Dec 5, 2025, 8:02 AM CET
40.17%
Market Cap 13.23B
Revenue (ttm) n/a
Net Income (ttm) -819.04M
Shares Out n/a
EPS (ttm) -4.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 198
Open 67.00
Previous Close 66.00
Day's Range 67.00 - 67.00
52-Week Range 26.80 - 69.00
Beta n/a
RSI 67.99
Earnings Date Feb 26, 2026

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Employees 534
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 42Z
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.